Avedro acquires assets of IROC Innocross

September 9, 2014

Avedro has purchased the assets of IROC Innocross, a Swish company that has commercialized a cross-linking device for the treatment of keratoconus and other corneal pathologies.

Waltham, MA-Avedro has purchased the assets of IROC Innocross, a Swish company that has commercialized a cross-linking device for the treatment of keratoconus and other corneal pathologies.

More in this issue: Aerie glaucoma eye drop treatment trial commences in Canada

According to Avedro, with the acquisition, the company’s platform of cross-linking technology will span the entire spectrum of corneal cross-linking procedures, from treating corneal pathology with Avedro’s UV-X devices and MedioCROSS riboflavin, enhancing LASIK outcomes with the KXL System and VibeX riboflavin, and to developing non-invasive refractive procedures with the advanced KXL II System.

“I am extremely pleased to have completed this important acquisition for Avedro,” said David Muller, PhD, chief executive officer of Avedro. “Under the direction of its founder, Prof. Michael Mrochen, IROC Innocross has firmly established the value of its UV-X devices.

“We look forward to immediately increasing our MedioCROSS riboflavin revenue through access to the established base of UV-X users and to further increasing device and riboflavin revenue by expanding sales of UV-X devices in all the markets we serve,” Dr. Muller continued.

Avedro will continue to work with IROC Innocross suppliers, MDP Solutions in Switzerland and Solnovis in Germany, to ensure product supply and development.

 

 

For more articles in this issue of Ophthalmology Times eReport, click here.

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.